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Abstract
Transforming growth factor-β (TGF-β) plays a crucial role in the pathogenesis of Systemic
Sclerosis (SSc) and other fibrotic disorders. TGF-β-mediated c-Abl and Src kinase activa-
tion induces strong profibrotic cascade signaling. The purpose of this study was to test in
vivo the antifibrotic activity of Bosutinib (SKI-606), a second generation c-Abl and Src kinase
inhibitor, on TGF-β induced cutaneous and pulmonary fibrosis. For this purpose, we
employed the TBRIcaCol1a2Cre transgenic mice expressing an inducible constitutively
active TGF-β receptor 1 constitutively activated by Col1a promoter-mediated Cre recombi-
nase. The mice were treated parenterally with 2.5, 5.0 or 10.0 mg/kg/day of Bosutinib for 42
days. Skin and lungs from control and Bosutinib-treated mice (n = 6 per group) were
assessed by histopathology, measurement of tissue hydroxyproline content, PCR analysis
of tissue fibrosis associated gene expression, and evidence of myofibroblast activation.
Mice with constitutive TGF-β-1 signaling displayed severe cutaneous and pulmonary fibro-
sis. Bosutinib administration decreased collagen deposition and hydroxyproline content in
the dermis and lungs in a dose-dependent manner. Bosutinib also reversed the marked
increase in profibrotic and myofibroblast activation-associated gene expression. These
results demonstrate that constitutive TGF-β-1-signaling-induced cutaneous and pulmonary
fibrosis were abrogated in a dose-related manner following parenteral administration of the
c-Abl and Src tyrosine kinase inhibitor, Bosutinib. These results indicate that Bosutinib may
be a potential therapeutic agent for tissue fibrosis in SSc and other fibroproliferative
disorders.
Introduction
Fibrotic disorders including Systemic Sclerosis (SSc) are characterized by exaggerated local or
systemic pathologic extracellular matrix (ECM) and fibrous tissue accumulation. These disor-
ders are responsible for high morbidity and mortality worldwide [1–7]. Despite distinct and
varied etiologies of fibrotic disorders and a remarkable heterogeneity in their clinical
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manifestations several common molecular mechanisms and signaling pathways regulate their
pathogenesis [8–11]. A hallmark of these diseases is the increased expression, production and
tissue accumulation of ECM proteins including the fibrillar types I, III and VI collagens and
fibronectin, disrupting the normal architecture of the affected organs resulting in their dys-
function and eventual failure. The chronic and progressive nature of fibrotic diseases, the large
array of affected organs, and the lack of effective disease modifying therapeutics render them a
challenge to efficient medical management [1–3,8]. The mortality attributed to fibrotic dis-
eases in Western countries may be as high as 45% or even higher in less developed and devel-
oping nations [1–3,8].
The fibroproliferative phenotype is largely mediated by activated myofibroblasts [12–15],
the cells responsible for the increased production of various ECM macromolecules, including
fibrillar type l, type lll, and type VI collagens and fibronectin, and a concomitant reduction of
ECM-degrading matrix metalloproteinase activity. Activated myofibroblasts are characterized
by the expression and production of α-smooth muscle actin (α-SMA), a protein that confers
these cells a contractile phenotype allowing their migration and the extension of tissue damage.
Although several cytokines and growth factors, such as transforming growth factor β (TGF-β),
platelet-derived growth factor (PDGF), and connective tissue growth factor, play important
roles in tissue fibrosis, the molecular pathways responsible are not completely understood
[9,16–19].
SSc is a systemic autoimmune disease characterized by exaggerated and often progressive
skin and multiple internal organ fibrosis leading to severe organ damage and high mortality
[4,5]. Although its etiology is unknown, TGF-β signaling is crucial in SSc pathogenesis
[5,9,17,18,20], rendering it an attractive target for SSc-disease-modifying therapies. In normal
cells, TGF-β isoforms initiate signaling following binding to membrane-associated serine/thre-
onine protein kinase TGF-β receptors [21]. The TGF-β type I and type II receptors (TBRI and
TBRII, respectively) are present as homodimers in the membrane. Binding of the dimerized
TGF-β ligand to the TBRII homodimer allows for the recruitment of the TBRI (also known as
ALK5) homodimer and triggers the formation of a mature heterotetramer receptor complex,
allowing the constitutively active TBRII kinase to autophosphorylate and then transphosphor-
ylate the TBRI kinase [22]. Signaling by this activated receptor complex can then proceed
through a canonical pathway or by one or more non-canonical pathways. In canonical TGF-β
signaling, the C-terminal regions of the SMAD2 and SMAD3 proteins [23,24] are phosphory-
lated by the activated TBRI [25], allowing association with the co-mediator SMAD4 and
nuclear accumulation of the SMAD2/3 complex where it can then regulate transcription of
downstream genes [26]. Several non-canonical signaling pathways that do not depend on
SMAD phosphorylation and nuclear accumulation have been described and include the mito-
gen activated protein kinases (MAPKs) ERK, p38 and JNK, PI3K/Akt and Rho GTPase path-
ways [27–29]. This diversity of signaling pathways involved mediate the pleiotropic
downstream effects of TGF-β on cellular and molecular processes. Upregulation of TGF-β and
its receptors [30–32] and of the TGF-β-regulated gene CCN2 or connective tissue growth fac-
tor (CTGF) also known as CCN2 has been reported in SSc fibroblasts and tissue samples [33],
although the increased expression of CCN2/CTGF is Smad3-independent but Smad1-depen-
dent [34,35]. Investigation of the role of TGF-β signaling in the induction of a fibrotic pheno-
type in SSc fibroblasts using small molecule inhibitors, antibodies, siRNA directed against the
TGF-β receptors or SMADs as well as knockout mouse models has indicated the involvement
and dysregulation of both canonical [36–38] and non-canonical [39–41] pathways.
Despite these studies implicating dysregulation of TGF-β signaling in mediating the induc-
tion of fibrosis in SSc, therapeutic approaches aimed at inhibition of TGF-β signaling have not
been successful, largely owing to serious side effects caused by inhibition of the multiple
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pleiotropic effects of TGF-β as well as by crosstalk with numerous associated molecular signal-
ing pathways. For example, metelimumab (CAT-192), a monoclonal antibody against TGF-β1,
induced significant morbidity and mortality in a study of 45 patients with early-stage diffuse
cutaneous SSc. CAT-192 also showed no evidence of efficacy compared to placebo as evaluated
by changes in the modified Rodnan skin thickness score (MRSS), assessment of organ-based
involvement and measurement of clinical biochemical parameters such as serum levels of solu-
ble interleukin-2 receptor, collagen propeptides or of tissue levels of mRNA for procollagens I
and III or for TGF-β1 [42]. A randomized, double-blind, multicenter, placebo-controlled trial
utilizing CAT-152, a monoclonal antibody directed against TGF-β2, to evaluate its effect in
preventing the progression of fibrosis in patients undergoing an initial trabeculectomy for pri-
mary open-angle or chronic angle-closure glaucoma demonstrated no statistically significant
improvement compared to the placebo group over the course of the 12 month study [43]. In
contrast, fresolimumab, an antibody that targets all three TGF-β isoforms improved clinical
symptoms in a small proof-of-concept study of 15 SSc patients for 24 weeks [44]. Clinical
improvement was measured by evaluating changes in the MRSS score as well as changes in the
expression levels of the TGF-β-regulated biomarker genes thrombospondin-1 (THBS1) and
cartilage oligomeric protein (COMP).
Modifying the activity of various tyrosine kinases to target tissue fibrosis has been intensely
investigated [45–48]. Recently much interest has focused on the non-receptor Src kinases
owing to their participation in various signal transduction pathways regulating important cel-
lular processes including cell migration, apoptosis, cytoskeletal rearrangements, and cellular
proliferation and differentiation [49–52]. Several profibrotic growth factors including PDGF
and TGF-β activate Src kinase signaling by stimulating the phosphorylation of a tyrosine resi-
due in its catalytic region [51,52]. Furthermore, several molecules involved in TGF-β-induced
conversion of quiescent fibroblasts to activated myofibroblasts, such as focal adhesion kinase
(FAK), hydrogen peroxide inducible gene 5 (HIC-5), myocardin-related transcription factor
(MRTFA), and extracellular signal-regulated kinase 1/2 (ERK1), are regulated by Src and con-
tribute to the persistent profibrotic phenotype of SSc fibroblasts [53–59]. Therefore, Src kinase
inhibitors represent potentially novel and effective agents for treating fibrotic diseases.
Imatinib mesylate, a small-molecule tyrosine kinase inhibitor that targets Abl kinase activity
associated with the Bcr-Abl translocation found in chronic myelogenous leukemia (CML) also
blocks the activity of PDGFR, c-kit and c-fms (also known as colony stimulating factor 1
receptor or CSF1R). Treatment of SSc fibroblasts in vitro with imatinib inhibited the expres-
sion and production of several extracellular matrix components, including both type I collagen
alpha 1 (Col1a1), and alpha 2 Col1a2 chains as well as fibronectin-1 in a dose-dependent man-
ner and did not induce compensatory changes in the expression of matrix metalloproteinases
or of tissue inhibitors of matrix metalloproteinases [60,61]. These effects were confirmed in
vivo utilizing several animal models of systemic and tissue-specific fibrosis [60–64]. Further-
more, several small case series and case reports in SSc patients have shown improvement [65–
67], and one study reported that imatinib induced improvement in two patients with Nephro-
genic Systemic Fibrosis [68]. A randomized, placebo-controlled, double-blind trial examining
the effect of imatinib treatment over 96 weeks in patients with idiopathic pulmonary fibrosis
found imatinib treatment was well tolerated in these patients, although there was no effect on
either survival or of clinical outcomes measures such as forced vital capacity, or other lung
functions compared to the placebo group [69]. Second generation Abl inhibitors dasatinib and
nilotinib have demonstrated similar anti-fibrotic effects in an animal model of fibrosis [70].
Bosutinib, or SKI-606 is a third-generation tyrosine kinase inhibitor developed to inhibit
the BCR-Abl kinase responsible for Philadelphia chromosome positive CML. Bosutinib was
approved for treating chronic-, accelerated-, and blast-phase CML in patients resistant to
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Imatinib [71,72]. Although BCR-Abl is not involved in tissue fibrosis pathogenesis, Bosutinib
also inhibits the profibrotic c-Abl tyrosine kinase [73]. Bosutinib is also a potent Src kinase
inhibitor, however, the kinase inhibitory effects of Bosutinib do not perturb the PDGF signal-
ing pathway whose inhibition has been associated with severe side effects [74,75]. Indeed,
Bosutinib therapy induces substantially less fluid retention and cardiac conduction problems
compared with the first- and second-generation Src inhibitors Imatinib and Nilotinib, respec-
tively [76].
The effects of Bosutinib on the expression and production of pro-fibrotic molecules and on
the phenotypic transition of normal to activated myofibroblasts in dermal fibroblasts from SSc
patients were examined previously in vitro [77]. The results showed a potent and dose-depen-
dent inhibition of the increased gene expression of the profibrotic extracellular matrix proteins
COL1A2, COL3A1, FN1 and of the profibrotic growth factor CTGF/CCN2 and a marked
reduction of the increased production of the corresponding proteins in cultured dermal SSc
fibroblasts. Bosutinib also abrogated the conversion of normal dermal fibroblasts into activated
myofibroblasts as assessed by cellular levels of the myofibroblast marker α-SMA and reversed
the abnormal profibrotic phenotype of dermal fibroblasts cultured from patients with diffuse
SSc of recent onset [77]. Additionally, the highest concentration of Bosutinib examined (5
nM) mediated a 30% reduction in the amount of secreted collagen in SSc fibroblasts and a
nearly 40% reduction in the amount of collagen and fibronectin in SSc fibroblast lysates. The
studies described here are, to our knowledge, the first demonstration of potent antifibrotic




All animal studies were reviewed and approved by the Institutional Animal Care and Use
Committee at Thomas Jefferson University. Mice overexpressing a constitutively-activated
fibroblast-specific form of the TGF-β receptor I under the control of the Col1α2 collagen gene
promoter requiring tamoxifen for activation (TBRIca Col1a2-Cre) were employed in these
studies. These mice develop extensive cutaneous and lung fibrosis following TBRIca expression
in fibroblasts. TBRIca activation in these mice (provided by Dr. Benoit de Crumbrugghe)
[78,79]was achieved by intraperitoneal injection of 1 mg 4-OH tamoxifen daily for 5 days.
Only male mice were used given the remarkable gender differences in tissue fibrosis extent
and severity [80,81]. Following the initial tamoxifen injection, mice were divided into 4 groups
of 6 mice each and anesthetized with ketamine and xylazine followed by implantation of sub-
dermal Alzet osmotic pumps (model #2006) containing either saline (control mice) or 2.5, 5.0
or 10.0 mg/kg/day Bosutinib dispensing their contents at a constant rate of 0.25 μl/hr for 42
days. Lidocaine was administered subcutaneously adjacent to the incision site pre- and post-
operatively to minimize discomfort of the animals.
Histopathological tissue analysis and determination of tissue
hydroxyproline content
All mice were sacrificed at 42 days post pump implantation by CO2 asphyxiation and full
thickness skin samples were excised from the dorsum of each mouse and both lungs were iso-
lated. A portion of each tissue sample was fixed in 10% buffered formalin, embedded in paraf-
fin, and sections (5 μM thickness) were obtained and stained with hematoxylin and eosin or
with Masson’s trichrome.
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A portion of the skin and lung samples isolated from each animal was weighed immediately
following removal and acid-hydrolyzed overnight in 6N HCl at 107˚C. The hydrolysates were
assayed for their total hydroxyproline content as described [82,83]. The hydroxyproline con-
tent per mg wet tissue was determined by comparing the absorbance of each sample to a stan-
dard curve generated by assay of known amounts of 4-hydroxyproline. The hydroxyproline
values were converted to amounts of collagen using a conversion factor of 7.5 since hydroxy-
proline represents ~13.5% of the amino acid content of collagen [82].
RNA isolation and real-time polymerase chain reaction (RT-PCR)
Total RNA was extracted from skin and lung samples using Trizol and first-strand cDNA was
generated using SuperScript II Reverse Transcriptase (Invitrogen). Transcript levels of genes
encoding ECM macromolecules, myofibroblast differentiation and activation proteins, and
downstream TGF-β transcription factors were determined using SYBR Green real-time PCR
as previously described [84,85]. Primers were designed using Primer Quest (Integrated DNA
Technologies) and were validated for specificity. The sequences of the primers employed are
shown in Table 1. Differences in mRNA transcript levels in each PCR were corrected for 18S
RNA endogenous control transcript levels; levels in control mice were set at 100% and all
other values were expressed as multiples of the control values.
Statistical analyses
Data are expressed as mean ± standard deviation. Statistical significance of changes in
gene expression levels or in hydroxyproline content was evaluated by Student’s t-test with
a p value <0.05 deemed significant.
Results
Effects of Bosutinib on dermal fibrosis induced by constitutive TGF-β
signaling in TBRIca-Col1a2-Cre mice
The antifibrotic effects of Bosutinib in vivo were examined employing a highly relevant murine
model of tissue fibrosis induced by TGF-β overexpression in fibroblasts [80,81]. These mice,
carrying a floxed constitutively active TGF-β receptor (TBRI) allele activated by tamoxifen-
Table 1. Sequence of primers used for RT-PCR.
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induced Cre recombinase expression under control of the fibroblast-specific Col1A2 promoter
develop extensive cutaneous and lung fibrosis [78,79]. The mice employed here may be a more
pathophysiologically relevant tissue fibrosis model than the more widely employed bleomycin-
induced fibrosis model [86,87]. Masson’s trichrome-stained full thickness skin sections from
saline-injected control mice displayed normal tissue architecture and collagen staining (Fig
1A), whereas tamoxifen-activated TBRIca-Col1a2-Cre mice skin demonstrated striking fibrosis
with a marked increase in dermal thickness, accumulation of densely packed and irregularly
arranged collagen bundles, and a marked increase in ECM collagen in the dermis and subder-
mal tissues (Fig 1A). The hypodermis also showed marked collagen infiltration and decreased
overall adipose layer thickness. Abnormal collagen deposition occurred between individual
muscle fibers of the panniculus carnosus in tamoxifen-injected animals compared with control
mice. The epidermis did not differ between the control and tamoxifen-activated groups.
Tamoxifen-injected TBRIca-Col1a2-Cre mice treated with Bosutinib dispensed continu-
ously for 42 days employing subdermal osmotic pumps displayed a dose-dependent decrease
in dermal fibrosis compared with saline control TBRIca-Col1a2-Cre animals injected with
tamoxifen (Fig 1A). Even in mice receiving only 2.5 mg/kg/day of Bosutinib dermal thickness
and collagen bundle accumulation were noticeably decreased. These changes were more evi-
dent in mice treated with 5 mg/kg/day Bosutinib with the maximal effect observed in 10 mg/
kg/day Bosutinib-treated mice that displayed near normal levels of collagen and ECM deposi-
tion in the dermis and essentially normal hypodermal tissue and subdermal muscle layers.
Effects of Bosutinib on pulmonary fibrosis induced by constitutive TGF-β
signaling in TBRIca-Col1a2-Cre mice
Trichrome staining of the lungs from untreated tamoxifen-injected animals displayed severe
alterations of the normal alveolar architecture with extensive areas of fibrosis causing alveolar
septae thickening and fibrotic parenchymal consolidation, compared to mock-injected (no
tamoxifen) control mice (Fig 1B). Marked interstitial, perivascular and peribronchiolar colla-
gen accumulation was present (Fig 1B). In contrast, tamoxifen-injected Bosutinib-treated
TBRIca-Col1a2-Cre mice (Fig 1B) displayed a dose-dependent decrease in pulmonary fibrosis
and alveolar/parenchymal abnormalities compared with animals injected with tamoxifen
alone. Even in mice receiving only 2.5 mg/kg/day of Bosutinib lung tissue consolidation and
collagen deposition were markedly decreased with substantially less alveolar architecture dis-
tortion. These improvements were more evident in 10 mg/kg/day Bosutinib-treated mice
which displayed near normal levels of collagen and ECM deposition and essentially complete
abrogation of tissue consolidation.
Hydroxyproline content in tissues of TBRIca-Col1a2-Cre mice
Hydroxyproline content of dorsal skin and lung samples was measured to assess quantitatively
the extent of collagen deposition. Skin samples from tamoxifen-injected untreated mice con-
tained approximately 1.5 fold greater hydroxyproline than control animals (Fig 2A). Bosutinib
treatment resulted in a dose-dependent decrease in skin collagen content with collagen levels
in skin from 10 mg/kg/day Bosutinib-treated mice not significantly different from the levels in
control mice. Lung samples from tamoxifen-injected mice contained approximately 1.9 fold
greater hydroxyproline than lungs from control mice (Fig 2B). Bosutinib treatment resulted in
a dose-dependent decrease in lung collagen content with the collagen levels in lung from 10
mg/kg/day Bosutinib-treated mice slightly but not significantly elevated compared to the levels
in control mice.
Bosutinib abrogates TGF-β-induced fibrosis in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0196559 May 2, 2018 6 / 17
Bosutinib abrogates TGF-β-induced fibrosis in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0196559 May 2, 2018 7 / 17
Bosutinib abrogates the increased expression of genes encoding ECM
macromolecules and myofibroblast differentiation proteins in tamoxifen-
treated TBRIca-Col1a2-Cre skin and lungs
Changes in expression of genes encoding relevant ECM and profibrotic proteins in the skin
and lungs of mice with constitutive TGF-β fibroblast signaling compared to saline-treated con-
trol mice were assessed by quantitative RT-PCR. Expression levels of the genes encoding
Fig 1. Histopathology of skin and lung from control, tamoxifen-injected untreated and tamoxifen-injected
Bosutinib-treated TBRIca-Col1a2-Cre transgenic mice. A. Skin. Skin sections from saline-treated tamoxifen-injected
TBRIca-Col1a2-Cre mice demonstrate increased dermal thickness and perivascular collagen accumulation
(magnification 10X, second left panel) compared to skin sections from saline-treated non-tamoxifen-injected control
mice (upper left panel). Skin sections from animals treated by subdermal osmotic pumps releasing 2.5 mg/kg/day, 5.0
mg/kg/day or 10 mg/kg/day of Bosutinib (left panels) display dose-dependent decreases in collagen deposition and
dermal thickness compared with untreated mice. B. Lung. Sections from lung from saline-treated TBRIca-Col1a2-Cre
tamoxifen-injected mice (magnification 10X, second left panel) demonstrate marked loss of alveolar morphology with
tissue consolidation and thickening of alveolar septae and perivascular and interstitial collagen accumulation compared
to lung sections from saline-treated non-tamoxifen-injected control mice (upper left panel). Lung sections from
animals treated by subdermal osmotic pumps releasing 2.5 mg/kg/day, 5.0 mg/kg/day or 10 mg/kg/day of Bosutinib
(left panels) display a dose-dependent partial restoration of alveolar morphology and decreased thickening of alveolar
septae and perivascular and interstitial collagen accumulation compared with the untreated mice.
https://doi.org/10.1371/journal.pone.0196559.g001
Fig 2. Hydroxyproline content of skin and lungs from control, tamoxifen-injected untreated and tamoxifen-injected Bosutinib-
treated TBRIca-Col1a2-Cre transgenic mice. A portion of skin (A) or lung (B) isolated from animals in each treatment group (n = 6)
was hydrolyzed and analyzed for hydroxyproline content. The results were converted to total collagen tissue content and are expressed
as μg/mg of tissue wet weight. The bars show the mean +/- standard error of each treatment group performed in triplicate. Significance
determined by Student’s two-tailed t test. : p<0.05, : p<0.01, : p<0.001.
https://doi.org/10.1371/journal.pone.0196559.g002
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Col1a1 and Col3a1 were upregulated in the skin by an average of 2.8 fold and 4.2 fold (Fig 3A),
respectively and in the lungs by 2.5 fold and 2.4 fold, respectively, compared to tamoxifen-
injected untreated mice (Fig 3B). Fn1 expression was increased by 2.2 fold in the skin (Fig 3A)
and by 4.8 fold in the lungs (Fig 3B) of tamoxifen-injected mice whereas the fibrosis-associated
splice variant Fn-Eda displayed 5.5 fold and 2.5 fold increased expression in the skin and lung,
respectively, compared to control animals. Acta2/α-Sma expression was increased 4 fold in the
skin (Fig 3A) and 3.4 fold in the lung (Fig 3B) compared to saline injected animals whereas
the levels of the growth factor Ctgf/Ccn2were increased 2.6 and 3.0 fold in the skin and lung,
respectively. Bosutinib treatment produced a marked and dose-dependent decrease in the
expression of all these genes in both skin and lung with the levels measured in 10 mg/kg/day
Bosutinib-treated mice only slightly elevated compared to control untreated mice.
Effect of Bosutinib on the increased Tgfb1 expression and of genes
encoding TGF-β1 pathway components in tamoxifen-treated TBRIca-
Col1a2-Cre skin and lungs
Profibrotic growth factor Tgfb1expression levels were upregulated by 3.4 fold in the skin and
by 3.9 fold in the lungs of tamoxifen-injected animals compared to control animals and
Fig 3. Expression of genes encoding ECM components in the skin and lungs from control, tamoxifen-injected untreated and
tamoxifen-injected Bosutinib-treated TBRIca-Col1a2-Cre transgenic mice. Expression of Col1a1, Col3a1, Fn1, and Fn-Eda in
skin (A) and lung (B). The values shown are the mean (+/- SD) fold change levels of gene expression from each treatment group
(n = 6) performed in triplicate for each tissue. Expression levels were normalized to 18S levels and the expression levels in untreated
controls. Values for other samples are expressed relative to the normalized control. Significance was determined by Student’s T-test.
Statistical significance: : p<0.05, : p<0.01, : p<0.001.
https://doi.org/10.1371/journal.pone.0196559.g003
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expression of its receptor Tgfbr1was upregulated 4 fold in the skin (Fig 4A) and 5.2 fold in the
lung (Fig 4B), reflecting tamoxifen-induced transgene expression and the subsequent para-
crine upregulation of TGF-β1 expression. Expression of the TGF-β-induced gene Comp was
upregulated in the skin and lungs of tamoxifen-injected mice by 2.7 fold and 3.0 fold respec-
tively (Fig 5A and 5B) and these increases were abrogated by Bosutinib. Bosutinib treatment
of the mice induced a dose-dependent decrease in expression of these genes however, even at
the 10 mg/kg/day dose, their expression remained significantly elevated compared to control
untreated mice.
Bosutinib abrogates the increased expression of genes encoding Erk1/2
protein kinases and Hic5
Expression levels of the TGF-β- and Src kinase-regulated Erk1 and Erk2 and of the TGF-β-
induced Hic5 gene were also examined. Erk1 levels were upregulated by 2.8 fold in the skin
and by 1.8 fold in the lungs of tamoxifen-injected mice compared to control mice and expres-
sion of the Erk2 kinase was upregulated 2.6 fold and 2.8 fold in the skin and lungs, respectively.
Hic5 expression levels increased 3.6 fold in the skin and 2.6 fold in the lungs of tamoxifen-
Fig 4. Expression of genes associated with myofibroblast transdifferentiation and with TGF-β signaling in the skin and lungs
from control, tamoxifen-injected untreated and tamoxifen-injected Bosutinib-treated TBRIca-Col1a2-Cre transgenic mice.
Expression of Acta2/Sma, Ctgf/Ccn2, Tgfb1, and Tgfbr1 in skin (A) and lung (B). The values shown are the mean (+/- SD) fold
change levels of gene expression from each treatment group (n = 6) performed in triplicate for each tissue. Expression levels were
normalized to 18S levels and the expression levels in untreated controls. Values for other samples are expressed relative to the
normalized control. Significance was determined by Student’s T-test. Statistical significance: : p<0.05, : p<0.01, : p<0.001.
https://doi.org/10.1371/journal.pone.0196559.g004
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injected mice (Fig 5A and 5B). Bosutinib treatment induced a dose-dependent decrease in
expression of these genes, and these levels were not significantly different in the 10 mg/kg/day
treated mice from those measured in the skin and lungs of saline-treated control animals.
Discussion
The effect of Bosutinib on the expression of genes encoding ECM components, regulation of
myofibroblast transdifferentiation and TGF-β1 production was previously examined in vitro
in SSc dermal fibroblasts [77]. Bosutinib induced a potent and dose-related inhibition of
COL1A2, COL3A1, FN1 and CTGF expression in SSc dermal fibroblasts and potent inhibition
of total collagen production by these cells. Intriguingly, the effect of Bosutinib on total collagen
production was highly selective for SSc dermal fibroblasts since only minimal effects on nor-
mal fibroblasts were observed. Importantly, Bosutinib also mediated a significant reduction in
the levels of α-SMA, a marker of myofibroblast activation of SSc fibroblasts [77]. The results of
these in vitro studies suggested that Bosutinib may represent a novel, selective and effective
antifibrotic agent for SSc therapy. The present study was performed to further validate this
suggestion in an in vivo animal model of tissue fibrosis. Bosutinib was tested in vivo employing
a highly relevant murine model of tissue fibrosis that possesses a fibroblast-specific tamoxifen-
Fig 5. Expression of the TBF-β target genes Comp and Erk1, Erk2 and the TGF-β-inducible Hic5 gene in the skin and lungs
from control, tamoxifen-injected untreated and tamoxifen-injected Bosutinib-treated TBRIca-Col1a2-Cre transgenic mice.
Expression of Comp, Erk1, Erk2, and Hic5 in skin (A) and lung (B). The values shown are the mean (+/- SD) fold change levels of
gene expression from each treatment group (n = 6) performed in triplicate for each tissue. Expression levels were normalized to 18S
levels and the expression levels in untreated controls. Values for other samples are expressed relative to the normalized control.
Significance was determined by Student’s T-test. Statistical significance: : p<0.05, : p<0.01, : p<0.001.
https://doi.org/10.1371/journal.pone.0196559.g005
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inducible constitutively active TGF-β receptor (TBRI) under control of the fibroblast-specific
Col1A2 gene [78,79]. This model reproduces more accurately the effects of upregulated TGF-β
signaling that has been associated with the establishment of a persistent profibrotic phenotype
in SSc [86,87].
Following tamoxifen-induced transgene expression activation, three doses (2.5, 5.0 or 10.0
mg/kg/day) of Bosutinib were administered to the TBRIca-Col1a2-Cre mice employing subder-
mal osmotic pumps that provide continuous release of Bosutinib over 42 days. Bosutinib
effects on the development of tissue fibrosis in skin and lungs were assessed by: 1) immunohis-
tochemistry; 2) measurement of tissue collagen content; 3) changes in the expression of genes
encoding various ECM components; and 4) assessment of the transdifferentiation of fibro-
blasts to profibrotic activated myofibroblasts. Bosutinib administration resulted in a marked
and dose-dependent decrease in skin and lung tissue fibrosis assessed by histopathologic anal-
ysis using Masson’s trichrome stain. In the skin, constitutive TGF-β signaling induced the
expected increase in collagen deposition and dermal thickness whereas Bosutinib-treated ani-
mals displayed decreased collagen deposition and dermal thicknesses compared with the
saline-treated animals. In the lung, constitutive TGF-β signaling induced dramatic tissue con-
solidation and alveolar thickening with abnormal and exaggerated perivascular and interstitial
collagen deposition, whereas in Bosutinib-treated mice a striking restoration or improvement
of tissue architecture and decreased collagen deposition was noted. These observations were
confirmed by the analysis of collagen deposition in the skin and lungs by measurement of
hydroxyproline levels. In both skin and lung, Bosutinib induced dose-dependent decreases in
hydroxyproline levels compared to control non-Bosutinib treated animals.
An analysis of profibrotic gene expression levels in response to Bosutinib revealed its effect
on multiple genes involved in the activation of myofibroblasts and encoding components of
the extracellular matrix that are regulated by TGF-β signaling. Col1a1, Col3a1, and Fn1 gene
expression increased following activation of TGF-β signaling in fibroblasts as did the expres-
sion of the fibrosis-specific splice variant Fn-Eda. Bosutinib decreased expression of these
genes in a dose-dependent manner, returning their expression levels to near the levels mea-
sured in non-tamoxifen control animals. A similar effect was observed on Acta2/Sma gene,
and on expression of genes encoding the TGF-β-induced proteins Comp and Hic5 and of the
TGF-β-regulated growth factor Ctgf/Ccn2. Expression of Tgfbr1, the receptor encoded by the
transgene was upregulated in tamoxifen-treated mice as was expression of Tgfb1. Bosutinib
reduced expression of these genes in a dose-dependent manner although they remained ele-
vated even at the 10 mg/kg/day dose most likely owing to the high level of transgene expres-
sion. The ability of Bosutinib to modify the TGF-β-mediated autocrine increased levels of
TGF-β and of the TGF-β receptors may represent one mechanism for the antifibrotic effects
that we observed in this model, however, since the levels of these genes remain upregulated
compared to the levels measured in control animals, the available evidence indicates that the
effects of Bosutinib on TGF-β-mediated skin and lung fibrosis are due to its suppression of the
ability of Src/c-Abl kinases to mediate the downstream effects of TGF-β signaling. Finally, the
expression levels of the genes encoding Erk1 and Erk2 kinases that were significantly upregu-
lated following activation of constitutive TGF-β signaling were reduced in a dose-dependent
manner following Bosutinib treatment.
In conclusion, Bosutinib displays potent anti-fibrotic effects in an in vivo model of TGF-β-
mediated tissue fibrosis, reducing the development of fibrosis in the skin and lungs of treated
animals in a dose-dependent manner as assessed by histopathologic analysis of collagen depo-
sition, by measurement of the levels of hydroxyproline as a biochemical analysis of total colla-
gen content in the isolated skin and lungs of these animals, and by the analysis of the
expression of genes encoding ECM components, markers of myofibroblast activation and
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differentiation, and of relevant profibrotic kinases and other TGF-β1 molecular targets. The
results obtained therefore extend the observations of the previously reported in vitro study of
the antifibrotic effects of Bosutinib in SSc dermal fibroblasts [40] to an in vivo transgenic
mouse model of TGF-β-mediated tissue fibrosis and overall reinforce the previously stated
conclusion that Bosutinib [77] may represent a novel, selective and effective antifibrotic agent
for therapy of SSc and other fibrotic disorders.
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